CENATAC

Summary

CENATAC (centrosomal AT-AC splicing factor, HGNC:30460) is a protein-coding gene on chromosome 11q23.3, encoding Centrosomal AT-AC splicing factor (Q86UT8). Component of the minor spliceosome that promotes splicing of a specific, rare minor intron subtype. It is a common-essential gene (DepMap: required in 99.3% of cancer cell lines).

This gene encodes a protein thought to contain a coiled coil motif. No function has been determined for the encoded protein. A pseudogene of this gene is located on chromosome 20. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 338657 — RefSeq curated summary.

At a glance

• Gene–disease (curated): mosaic variegated aneuploidy syndrome 4 (Limited, GenCC)
• Clinical variants (ClinVar): 87 total — 2 pathogenic
• Phenotypes (HPO): 4
• Cancer dependency (DepMap): dependent in 99.3% of screened cell lines (common-essential)
• MANE Select transcript: NM_198489

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30460
Approved symbol	CENATAC
Name	centrosomal AT-AC splicing factor
Location	11q23.3
Locus type	gene with protein product
Status	Approved
Aliases	DLNB14
Ensembl gene	ENSG00000186166
Ensembl biotype	protein_coding
OMIM	620142
Entrez	338657

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 6 retained_intron, 3 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000334418, ENST00000524670, ENST00000526463, ENST00000527356, ENST00000528088, ENST00000532132, ENST00000533787, ENST00000534656, ENST00000580556, ENST00000583842, ENST00000891520, ENST00000937690

RefSeq mRNA: 1 — MANE Select: NM_198489 NM_198489

CCDS: CCDS8405

Canonical transcript exons

ENST00000334418 — 11 exons

Exon	Start	End
ENSE00001336373	119011221	119011283
ENSE00001336377	119015538	119015793
ENSE00001336378	118998138	118998317
ENSE00003471497	119015307	119015439
ENSE00003476708	118998430	118998593
ENSE00003536694	118999011	118999109
ENSE00003555622	119012149	119012254
ENSE00003555873	119014994	119015083
ENSE00003565648	119010764	119010830
ENSE00003637325	119013232	119013262
ENSE00003691033	119011939	119012003

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 95.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.2985 / max 198.2184, expressed in 1784 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
117080	15.2560	1770
117078	0.5539	340
117079	0.4886	288

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar cortex	UBERON:0002129	95.95	gold quality
cerebellar hemisphere	UBERON:0002245	95.93	gold quality
mucosa of stomach	UBERON:0001199	95.86	gold quality
cerebellum	UBERON:0002037	95.86	gold quality
sural nerve	UBERON:0015488	95.74	gold quality
adenohypophysis	UBERON:0002196	95.58	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.43	gold quality
metanephros cortex	UBERON:0010533	95.32	gold quality
granulocyte	CL:0000094	95.15	gold quality
pituitary gland	UBERON:0000007	95.15	gold quality
upper lobe of left lung	UBERON:0008952	95.14	gold quality
spleen	UBERON:0002106	95.11	gold quality
left lobe of thyroid gland	UBERON:0001120	94.95	gold quality
right lung	UBERON:0002167	94.93	gold quality
apex of heart	UBERON:0002098	94.87	gold quality
right lobe of thyroid gland	UBERON:0001119	94.84	gold quality
primary visual cortex	UBERON:0002436	94.83	gold quality
tibial nerve	UBERON:0001323	94.68	gold quality
thyroid gland	UBERON:0002046	94.63	gold quality
skin of leg	UBERON:0001511	94.62	gold quality
skin of abdomen	UBERON:0001416	94.61	gold quality
zone of skin	UBERON:0000014	94.60	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.36	gold quality
right uterine tube	UBERON:0001302	94.19	gold quality
cortex of kidney	UBERON:0001225	93.97	gold quality
ectocervix	UBERON:0012249	93.79	gold quality
uterine cervix	UBERON:0000002	93.72	gold quality
thoracic mammary gland	UBERON:0005200	93.68	gold quality
body of pancreas	UBERON:0001150	93.65	gold quality
endocervix	UBERON:0000458	93.60	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.56
E-MTAB-4850	no	128.49

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting CENATAC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-4718	98.55	68.61	814
HSA-MIR-654-3P	98.38	67.61	905
HSA-MIR-218-2-3P	98.08	67.21	601
HSA-MIR-152-5P	96.42	66.59	960
HSA-MIR-584-5P	95.82	68.05	848

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.3% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 2)

• CCDC84 Acetylation Oscillation Regulates Centrosome Duplication by Modulating HsSAS-6 Degradation. (PMID:31722219)
• Chromosomal instability by mutations in the novel minor spliceosome component CENATAC. (PMID:34009673)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cenatac	ENSDARG00000059606
mus_musculus	Cenatac	ENSMUSG00000043923
rattus_norvegicus	Cenatac	ENSRNOG00000012137

Protein

Protein identifiers

Centrosomal AT-AC splicing factor — Q86UT8 (reviewed: Q86UT8)

Alternative names: Coiled-coil domain-containing protein 84

All UniProt accessions (3): E9PJ16, E9PPT8, Q86UT8

UniProt curated annotations — full annotation on UniProt →

Function. Component of the minor spliceosome that promotes splicing of a specific, rare minor intron subtype. Negative regulator of centrosome duplication. Constrains centriole number by modulating the degradation of the centrosome-duplication-associated protein SASS6 in an acetylation-dependent manner. SIRT1 deacetylates CENATAC in G1 phase, allowing for SASS6 accumulation on the centrosome and subsequent procentriole assembly. The CENATAC acetylation level is restored in mitosis by NAT10, promoting SASS6 proteasome degradation by facilitating SASS6 binding to APC/C E3 ubiquitin-protein ligase complex/FZR1.

Subunit / interactions. Interacts with SASS6; the interaction increases with CENATAC acetylation.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome.

Post-translational modifications. Acetylated. Acetylation oscillates throughout the cell cycle, and the acetylation state at Lys-31 is regulated by the deacetylase SIRT1 and the acetyltransferase NAT10. Deacetylated CENATAC is responsible for its centrosome targeting, and acetylated CENATAC promotes SASS6 degradation by enhancing the binding affinity of SASS6 for APC/C E3 ubiquitin-protein ligase complex/FZR1.

Disease relevance. Mosaic variegated aneuploidy syndrome 4 (MVA4) [MIM:620153] A form of mosaic variegated aneuploidy syndrome, a severe disorder characterized by mosaic aneuploidies, predominantly trisomies and monosomies, involving multiple different chromosomes and tissues. Affected individuals typically present with severe intrauterine growth retardation and microcephaly. Eye anomalies, mild dysmorphism, variable developmental delay, and a broad spectrum of additional congenital abnormalities and medical conditions may also occur. The risk of malignancy is high, with rhabdomyosarcoma, Wilms tumor and leukemia reported in several cases. MVA4 inheritance is autosomal recessive. The disease is caused by variants affecting the gene represented in this entry.

RefSeq proteins (1): NP_940891* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028015	CCDC84-like	Family

Pfam: PF14968

UniProt features (9 total): region of interest 2, mutagenesis site 2, chain 1, coiled-coil region 1, compositionally biased region 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8Y6O	ELECTRON MICROSCOPY	3.38

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UT8-F1	76.92	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 31

Mutagenesis-validated functional residues (2):

Position	Phenotype
31	increases interaction with sass6.
31	strongly reduces acetylation. no effect on interaction with sass6.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 104 (showing top): GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_CHROMOSOME_SEPARATION, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_SPLICEOSOMAL_TRI_SNRNP_COMPLEX_ASSEMBLY, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE, GOCC_CENTROSOME, GOBP_REGULATION_OF_CENTROSOME_CYCLE, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RNA_SPLICING

GO Biological Process (6): mRNA splicing, via spliceosome (GO:0000398), negative regulation of centrosome duplication (GO:0010826), regulation of protein catabolic process (GO:0042176), chromosome separation (GO:0051304), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): centrosome (GO:0005813), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
regulation of centrosome duplication	1
negative regulation of centrosome cycle	1
centrosome duplication	1
regulation of catabolic process	1
protein catabolic process	1
regulation of protein metabolic process	1
chromosome segregation	1
cell cycle process	1
mRNA metabolic process	1
binding	1
centriole	1
microtubule organizing center	1
intracellular anatomical structure	1
cellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

430 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CENATAC	C6orf52	Q5T4I8	613
CENATAC	ENTR1	Q96C92	528
CENATAC	DYNC1LI2	O43237	499
CENATAC	CCDC107	Q8WV48	489
CENATAC	MRPL40	Q9NQ50	484
CENATAC	TMEM87A	Q8NBN3	475
CENATAC	CCDC190	Q86UF4	431
CENATAC	CCP110	O43303	427
CENATAC	TEPSIN	Q96N21	426
CENATAC	CCDC169	A6NNP5	424
CENATAC	KATNIP	O60303	423
CENATAC	CCDC74B	Q96LY2	419
CENATAC	SNRNP48	Q6IEG0	419
CENATAC	TMEM208	Q9BTX3	418
CENATAC	INTS10	Q9NVR2	407

IntAct

53 interactions, top by confidence:

A	B	Type	Score
SNRPF	GEMIN2	psi-mi:“MI:0914”(association)	0.910
CENATAC	TXNL4B	psi-mi:“MI:0915”(physical association)	0.770
SNRPE	GEMIN2	psi-mi:“MI:0914”(association)	0.770
PRPF3	PRPF4	psi-mi:“MI:0914”(association)	0.730
SNRPG	GEMIN2	psi-mi:“MI:0914”(association)	0.710
SNRPB	SART1	psi-mi:“MI:0914”(association)	0.640
CENATAC	ZNF114	psi-mi:“MI:0915”(physical association)	0.560
CENATAC	MRPL38	psi-mi:“MI:0915”(physical association)	0.560
MESD	CENATAC	psi-mi:“MI:0915”(physical association)	0.560
CENATAC	PPIL3	psi-mi:“MI:0915”(physical association)	0.560
CENATAC	NDOR1	psi-mi:“MI:0915”(physical association)	0.560
KLC2	KIF5B	psi-mi:“MI:0914”(association)	0.530
G3BP1	COX5A	psi-mi:“MI:0914”(association)	0.530
SNRPE	PRMT5	psi-mi:“MI:0914”(association)	0.530
CENATAC	GINS1	psi-mi:“MI:0914”(association)	0.530
SNRPE	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
ADARB1	SPTY2D1	psi-mi:“MI:0914”(association)	0.530
MAGEB2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
ECE1	CENATAC	psi-mi:“MI:0915”(physical association)	0.370
YWHAZ	WDR62	psi-mi:“MI:0914”(association)	0.350
PRPF4		psi-mi:“MI:0914”(association)	0.350
Srp72		psi-mi:“MI:0914”(association)	0.350
Mtx2	NRDC	psi-mi:“MI:0914”(association)	0.350
Jup		psi-mi:“MI:0914”(association)	0.350
PIM2	NUP98	psi-mi:“MI:0914”(association)	0.350
Tgs1	EFCAB5	psi-mi:“MI:0914”(association)	0.350

BioGRID (74): PRPF3 (Affinity Capture-MS), TUT1 (Affinity Capture-MS), SART3 (Affinity Capture-MS), WDR83 (Affinity Capture-MS), DCAF5 (Affinity Capture-MS), TXNL4B (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS), CCDC84 (Affinity Capture-MS)

ESM2 similar proteins: A4D161, A6H7A8, E1BGQ2, O70524, O75391, P29084, P29540, P70445, Q14161, Q15650, Q28J59, Q2KJF9, Q2NL14, Q2VPL9, Q32LC9, Q32NC0, Q3ZK22, Q4V8D7, Q4VA36, Q5R595, Q5R802, Q5R9D9, Q5RFL7, Q5XI52, Q5ZJK1, Q66H91, Q6AY70, Q7TNE3, Q861R7, Q86UT8, Q8BND4, Q8BQR4, Q8BXK4, Q8C790, Q8IWR0, Q8K2I9, Q8NFZ0, Q8VDD9, Q8WWQ0, Q922H9

Diamond homologs: F4JRR5, Q4VA36, Q86UT8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 44 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metabolism of non-coding RNA	5	117.5×	4e-08
snRNP Assembly	7	54.8×	5e-09
SARS-CoV-2 modulates host translation machinery	5	41.5×	2e-06
RNA Polymerase II Transcription Termination	5	40.7×	2e-06
mRNA Splicing	6	24.4×	2e-06
SARS-CoV-2-host interactions	5	22.0×	4e-05
Processing of Capped Intron-Containing Pre-mRNA	6	18.3×	1e-05
mRNA Splicing - Major Pathway	9	18.2×	4e-08

GO biological processes:

GO term	Partners	Fold	FDR
spliceosomal snRNP assembly	7	109.9×	4e-11
mRNA splicing, via spliceosome	10	24.8×	6e-10
RNA splicing	7	16.7×	9e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	71
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2627019	NM_198489.3(CENATAC):c.805+2_805+19del	Pathogenic
2627020	NM_198489.3(CENATAC):c.803A>T (p.Glu268Val)	Pathogenic

SpliceAI

1695 predictions. Top by Δscore:

Variant	Effect	Δscore
11:118998291:G:GT	donor_gain	1.0000
11:118998314:CCAG:C	donor_loss	1.0000
11:118998315:CAGGT:C	donor_loss	1.0000
11:118998316:AGG:A	donor_loss	1.0000
11:118998317:GGTG:G	donor_loss	1.0000
11:118999006:TTCA:T	acceptor_loss	1.0000
11:118999007:TCA:T	acceptor_loss	1.0000
11:118999009:A:AG	acceptor_gain	1.0000
11:118999010:G:GC	acceptor_gain	1.0000
11:118999010:GC:G	acceptor_gain	1.0000
11:118999010:GCCC:G	acceptor_gain	1.0000
11:118999010:GCCCA:G	acceptor_gain	1.0000
11:119010829:AGG:A	donor_loss	1.0000
11:119010831:G:C	donor_loss	1.0000
11:119010832:T:A	donor_loss	1.0000
11:119014989:TTCA:T	acceptor_loss	1.0000
11:119014990:TCA:T	acceptor_loss	1.0000
11:119014991:CAG:C	acceptor_loss	1.0000
11:119014992:A:AG	acceptor_gain	1.0000
11:119014992:AG:A	acceptor_gain	1.0000
11:119014992:AGGT:A	acceptor_gain	1.0000
11:119014993:G:GA	acceptor_gain	1.0000
11:119014993:GG:G	acceptor_gain	1.0000
11:119014993:GGT:G	acceptor_gain	1.0000
11:119014993:GGTG:G	acceptor_gain	1.0000
11:119014993:GGTGC:G	acceptor_gain	1.0000
11:119015079:AGAAA:A	donor_gain	1.0000
11:119015080:GAAA:G	donor_gain	1.0000
11:119015080:GAAAG:G	donor_gain	1.0000
11:119015081:A:T	donor_gain	1.0000

AlphaMissense

2182 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:119015399:T:C	F300L	0.999
11:119015401:T:A	F300L	0.999
11:119015401:T:G	F300L	0.999
11:119015411:T:A	W304R	0.999
11:119015411:T:C	W304R	0.999
11:119015413:G:C	W304C	0.999
11:119015413:G:T	W304C	0.999
11:119015008:T:A	W244R	0.998
11:119015008:T:C	W244R	0.998
11:119015387:T:A	W296R	0.998
11:119015387:T:C	W296R	0.998
11:119015357:T:C	F286L	0.997
11:119015359:T:A	F286L	0.997
11:119015359:T:G	F286L	0.997
11:119015389:G:C	W296C	0.996
11:119015389:G:T	W296C	0.996
11:119015403:G:A	G301D	0.996
11:119015412:G:C	W304S	0.996
11:119015426:C:A	R309S	0.996
11:119015545:T:C	F316L	0.996
11:119015547:C:A	F316L	0.996
11:119015547:C:G	F316L	0.996
11:119015343:G:C	R281P	0.995
11:119015400:T:G	F300C	0.995
11:119015010:G:C	W244C	0.994
11:119015010:G:T	W244C	0.994
11:118999040:T:C	F105S	0.993
11:118999042:T:A	W106R	0.993
11:118999042:T:C	W106R	0.993
11:119015349:G:A	G283E	0.993

dbSNP variants (sampled 300 via entrez): RS1000121364 (11:119015770 A>G), RS1000313978 (11:118996719 C>T), RS1000433036 (11:119010632 C>A,T), RS1000448558 (11:119011864 C>A,G,T), RS1000559872 (11:119005258 A>C,G), RS1000762085 (11:118999526 TC>T), RS1000816683 (11:119013502 C>A,G,T), RS1000998911 (11:119006202 T>G), RS1001030223 (11:119006617 C>G), RS1001085941 (11:119000537 T>C), RS1001411603 (11:118996996 A>G), RS1001464050 (11:118997314 T>C,G), RS1001526503 (11:119011226 A>G), RS1001746295 (11:119016060 G>A), RS1001757740 (11:119002495 C>G,T)

Disease associations

OMIM: gene MIM:620142 | disease phenotypes: MIM:620153

GenCC curated gene-disease

Disease	Classification	Inheritance
mosaic variegated aneuploidy syndrome 4	Limited	Autosomal recessive

Mondo (1): mosaic variegated aneuploidy syndrome 4 (MONDO:0859329)

Orphanet (0):

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000252	Microcephaly
HP:0003220	Abnormality of chromosome stability
HP:0011342	Mild global developmental delay

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
bisphenol A	increases expression, affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Particulate Matter	decreases expression, decreases reaction	2
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Decitabine	affects expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Atrazine	decreases expression	1
Vehicle Emissions	decreases expression, decreases reaction	1
Cadmium	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Cisplatin	affects expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Formaldehyde	increases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Manganese	decreases expression, increases abundance, affects cotreatment	1
Methyl Methanesulfonate	increases expression	1
Silicon Dioxide	increases expression	1
Silver	increases expression	1
Smoke	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.